The trading price of Amneal Pharmaceuticals, Inc. (NYSE:AMRX) closed higher on Tuesday, Jan 12, closing at $4.75, 2.32% higher than its previous close.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Traders who pay close attention to intraday price movement should know that it fluctuated between $4.8100 and $5.3300. The company’s P/E ratio in the trailing 12-month period was 11.88, while its 5Y monthly beta was 1.26. In examining the 52-week price action we see that the stock hit a 52-week high of $5.68 and a 52-week low of $2.4. Over the past month, the stock has gained 15.99% in value.

Amneal Pharmaceuticals, Inc., whose market valuation is $1.51 Billion at the time of this writing, is expected to release its quarterly earnings report in Feb 2021. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by $0.13 per share this quarter, however they have predicted annual earnings per share of $0.62 for 2021 and $0.7 for 2022. It means analysts are expecting annual earnings per share growth of 0.77% this year and 0.13% next year.

Analysts have forecast the company to bring in revenue of $504.44 Million for the quarter, with the likely lows of $477.7 Million and highs of $516.59 Million. The average estimate suggests sales will likely up by 27% this quarter compared to what was recorded in the comparable quarter last year. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2021 is $1.99 Billion. The company’s revenue is forecast to grow by +22.2% over what it did in 2020.

On the technical side, indicators suggest AMRX has a 100% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Buy, while an average of long term indicators suggests that the stock is currently 100% Buy.

Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned AMRX a recommendation rating is 12. Out of them, 6 rate it a Hold, while 4 recommend Buy, whereas none assign an Outperform rating. None analyst(s) have tagged Amneal Pharmaceuticals, Inc. (AMRX) as Underperform, while 2 advise Sell. Analysts have rated the stock Hold, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.

If we dig deeper into the stock’s outlook, we see that the stock’s PEG is 0, which symbolizes a positive outlook. A quick review shows that AMRX’s price is currently 6.36% off the SMA20 and 11.53% off the SMA50. The RSI metric on the 14-day chart is currently showing 61.26, and weekly volatility stands at 6.95%. When measured over the past 30 days, the indicator reaches 5.17%. Amneal Pharmaceuticals, Inc. (NYSE:AMRX)’s beta value is currently sitting at 1.26, while the Average True Range indicator is currently displaying 0.25. With analysts defining $3-$6 as the low and high price targets, we arrive at a consensus price target of $4.9 for the trailing 12-month period. The current price is about -38.27% off the estimated low and 23.46% off the forecast high, based on this estimate. Investors will be thrilled if AMRX’s share price rises to $5, which is the median consensus price. At that level, AMRX’s share price would be +2.88% above current price.

To see how Amneal Pharmaceuticals, Inc. stock has been performing in comparison to its peers in the industry, here are the numbers: AMRX stock’s performance was +2.32% in the latest trading, and +8% in the past year, while Zoetis Inc Cl A (ZTS) has traded -1.93% on the day and positioned +21.69% higher than it was a year ago. Another comparable company Takeda Pharmaceutical CO Ltd (TAK) saw its stock close -0.27% lower in the most recent trading session but was down -8.42% in a year. Furthermore, Catalent Inc (CTLT) showed an increase of 2.32% on the day while its price kept rising at 8% over the past year. Amneal Pharmaceuticals, Inc. has a P/E ratio of 11.88, compared to Zoetis Inc Cl A’s 47.69 and Takeda Pharmaceutical CO Ltd’s 22.51. Also in last trading session, the S&P 500 Index has surged 0.04%, while the Dow Jones Industrial also saw a positive session, up +0.19% on the day.

An evaluation of the daily trading volume of Amneal Pharmaceuticals, Inc. (NYSE:AMRX) indicates that the 3-month average is 1.17 Million. However, this figure has increased over the past 10 days to an average of 1.36 Million.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Currently, records show that 147.63 Million of the company’s shares remain outstanding. According to Thomson Reuters data, insiders hold 10.43% of outstanding shares, whereas institutions hold 69.86%. The stats also highlight that short interest as of December 14, 2020, stood at 6.53 Million shares, resulting in a short ratio of 6.08 at that time. From this, we can conclude that short interest is 4.42% of the company’s total outstanding shares. It is noteworthy that short shares in December were down slightly from the previous month’s figure, which was 6.61 Million. However, since the stock’s price has seen +6.35% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.


A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on..

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets are already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
.

Sponsored


Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

LEAVE A REPLY

Please enter your comment!
Please enter your name here